Literature DB >> 19273278

Control of cell death pathways by HTLV-1 proteins.

Daniela Saggioro1, Micol Silic-Benussi, Roberta Biasiotto, Donna M D'Agostino, Vincenzo Ciminale.   

Abstract

Individuals infected with HTLV-1 harbor the virus mainly in CD4+ memory T-cells as a lifelong infection that remains subclinical in the majority of cases. However, about 3-5% of HTLV-1-infected individuals develop an aggressive T-cell neoplasia (ATLL) or a neurodegenerative disease (TSP/HAM) after a latency period ranging from years to decades. This review summarizes the current knowledge of the effects of the HTLV-1 proteins Tax, p13 and p12 on cell death and survival pathways. Tax, the major oncogenic determinant of HTLV-1, enhances cell survival through its effects on the NF-kappaB, CREB and AKT pathways and on the tumor suppressors p53 and Rb. p13 is targeted to the inner mitochondrial membrane and sensitizes cells to the Fas/ceramide apoptotic pathway and reactive oxygen species-mediated cell death. p12 enhances release of calcium from the endoplasmic reticulum and therefore may influence calcium-dependent apoptotic signals, including opening of the mitochondrial permeability transition pore. The long-term fate of HTLV-1-infected cells (apoptosis, survival, transformation) may therefore depend on the balance of the effects of Tax, p13 and p12 on cell death pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273278     DOI: 10.2741/3456

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  21 in total

Review 1.  HTLV-1 p13, a small protein with a busy agenda.

Authors:  Micol Silic-Benussi; Roberta Biasiotto; Vibeke Andresen; Genoveffa Franchini; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Mol Aspects Med       Date:  2010-03-21

2.  Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses.

Authors:  Young Bong Choi; Edward William Harhaj
Journal:  Front Biol (Beijing)       Date:  2014-12

3.  The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome.

Authors:  Alexandra Oteiza; Nadir Mechti
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

4.  Highly pathogenic H5N1 avian influenza virus induces extracellular Ca2+ influx, leading to apoptosis in avian cells.

Authors:  Mayo Ueda; Tomo Daidoji; Anariwa Du; Cheng-Song Yang; Madiha S Ibrahim; Kazuyoshi Ikuta; Takaaki Nakaya
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

5.  Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo.

Authors:  Linda Zane; David Sibon; Lionel Jeannin; Marc Zandecki; Marie-Hélène Delfau-Larue; Antoine Gessain; Olivier Gout; Christiane Pinatel; Agnès Lançon; Franck Mortreux; Eric Wattel
Journal:  Retrovirology       Date:  2010-03-11       Impact factor: 4.602

6.  The viral oncoprotein tax sequesters DNA damage response factors by tethering MDC1 to chromatin.

Authors:  S Mehdi Belgnaoui; Kimberly A Fryrear; Julius O Nyalwidhe; Xin Guo; O John Semmes
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

Review 7.  The modulation of apoptosis by oncogenic viruses.

Authors:  Alma Mariana Fuentes-González; Adriana Contreras-Paredes; Joaquín Manzo-Merino; Marcela Lizano
Journal:  Virol J       Date:  2013-06-06       Impact factor: 4.099

8.  Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis.

Authors:  Priya Kannian; Patrick L Green
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

9.  Reduced levels of reactive oxygen species correlate with inhibition of apoptosis, rise in thioredoxin expression and increased bovine leukemia virus proviral loads.

Authors:  Amel Baya Bouzar; Mathieu Boxus; Arnaud Florins; Carole François; Michal Reichert; Luc Willems
Journal:  Retrovirology       Date:  2009-11-10       Impact factor: 4.602

10.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.